Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | February 06, 2019 | February 08, 2019 |
| Kronos Bio, Inc.KRON · Entity 78257 | Director | October 14, 2020 | October 16, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | March 03, 2021 | March 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,887,225 |
Ending reported balance
After 2019-02-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-02-06 · Grant · Acquired 7,745 · Balance 2,885,507 F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 2 · 2019-02-06 · Grant · Acquired 15,505 · Balance 2,901,012 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 3 · 2019-02-06 · Tax withholding · Disposed 13,787 · Balance 2,887,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
Kronos Bio, Inc.
Report date October 14, 2020 · Filed October 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,952,364 |
Last balance in matching sequence
After 2020-10-14 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-10-14 · Conversion · Acquired 914,333 · Balance 914,333 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 2 · 2020-10-14 · Conversion · Acquired 756,971 · Balance 1,671,304 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 3 · 2020-10-14 · Conversion · Acquired 205,260 · Balance 1,876,564 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 4 · 2020-10-14 · Purchase · Acquired 75,800 · Balance 1,952,364 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-14 · Conversion · Disposed 866,667 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-14 · Conversion · Disposed 717,509 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2022-02-20 | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-14 · Conversion · Disposed Not disclosed · Balance 0 F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.
Sarepta Therapeutics, Inc.
Report date March 03, 2021 · Filed March 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,913 |
Reported balance
After 2021-03-03 transaction · row 1
1 source rowRow 1 · 2021-03-03 · Grant · Acquired 2,726 · Balance 7,913 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.11 · Expires 2031-03-03 | Direct | 5,518 |
Reported balance
After 2021-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-03 · Grant · Acquired 5,518 · Balance 5,518 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2021 Filed Mar 6, 2021 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 5,518 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018418 · doc4.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,518 Underlying: Common Stock · 5,518 shares Expires 2031-03-03 Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018418 · doc4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,913 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 15:51 UTC | Kronos Bio, Inc. KRON · Entity 78257 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $16.15 | $3,314,963.25 |
DisclosureSEC source: 0001209191-20-055042 · doc4.xml · derivative · entry 7 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 205,260 shares Expires 2022-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 15:51 UTC | Kronos Bio, Inc. KRON · Entity 78257 | ConversionSeries A Preferred Stock · Derivative | 717,509 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055042 · doc4.xml · derivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 756,971 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 15:51 UTC | Kronos Bio, Inc. KRON · Entity 78257 | ConversionSeries Seed Preferred Stock · Derivative | 866,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055042 · doc4.xml · derivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 914,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 15:51 UTC | Kronos Bio, Inc. KRON · Entity 78257 | PurchaseCommon Stock | 75,800 | $19.00 | $1,440,200.00 |
DisclosureSEC source: 0001209191-20-055042 · doc4.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,952,364 F2 · ownership.nature: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 15:51 UTC | Kronos Bio, Inc. KRON · Entity 78257 | ConversionCommon Stock | 205,260 | $16.15 | $3,314,949.00 |
DisclosureSEC source: 0001209191-20-055042 · doc4.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,876,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 15:51 UTC | Kronos Bio, Inc. KRON · Entity 78257 | ConversionCommon Stock | 756,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055042 · doc4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,671,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 15:51 UTC | Kronos Bio, Inc. KRON · Entity 78257 | ConversionCommon Stock | 914,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055042 · doc4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 914,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014229 · doc4.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2020-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 5,528 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014229 · doc4.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,528 Underlying: Common Stock · 5,528 shares Expires 2020-02-28 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014229 · doc4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,187 F2 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 3,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014229 · doc4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,112 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs vest in three equal annual installments beginning February 28, 2021. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 13,787 | $68.75 | $947,856.25 |
DisclosureSEC source: 0001127602-19-004859 · form4.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,887,225 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 15,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004859 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,901,012 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 7,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-004859 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,885,507 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 01:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-035244 · form4.xml · derivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to the option have a five year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 01:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $72.67 | $14,533.00 |
DisclosureSEC source: 0001127602-18-035244 · form4.xml · nonDerivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,877,762 F6 · price: Sale prices reported for the transactions reported here range from $72.59 to $72.74. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 01:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 13,958 | $71.95 | $1,004,275.31 |
DisclosureSEC source: 0001127602-18-035244 · form4.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,877,962 F5 · price: Sale prices reported for the transactions reported here range from $71.56 to $72.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 01:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 35,842 | $70.90 | $2,541,369.84 |
DisclosureSEC source: 0001127602-18-035244 · form4.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,891,920 F4 · price: Sale prices reported for the transactions reported here range from $70.55 to $71.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 01:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $23.60 | $1,180,000.00 |
DisclosureSEC source: 0001127602-18-035244 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,927,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 29, 2018 Filed Dec 5, 2018 01:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 140,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-035244 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,877,762 F1 · shares: Shares gifted to charitable trust Read SEC document |
| November 01, 2018 Filed Nov 6, 2018 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-032174 · form4.xml · derivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a five year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 01, 2018 Filed Nov 6, 2018 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 13,579 | $70.15 | $952,632.03 |
DisclosureSEC source: 0001127602-18-032174 · form4.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017,762 F5 · price: Sale prices reported for the transactions reported here range from $70.05 to $70.40. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 01, 2018 Filed Nov 6, 2018 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 28,421 | $69.53 | $1,976,134.87 |
DisclosureSEC source: 0001127602-18-032174 · form4.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,031,341 F4 · price: Sale prices reported for the transactions reported here range from $68.04 to $70.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 01, 2018 Filed Nov 6, 2018 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,000 | $68.61 | $548,850.40 |
DisclosureSEC source: 0001127602-18-032174 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,059,762 F3 · price: Sale prices reported for the transactions reported here range from $68.03 to $69.03. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 01, 2018 Filed Nov 6, 2018 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $23.60 | $1,180,000.00 |
DisclosureSEC source: 0001127602-18-032174 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-029453 · form4.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a five year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,670 | $78.34 | $1,305,852.79 |
DisclosureSEC source: 0001127602-18-029453 · form4.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017,762 F4 · price: Sale prices reported for the transactions reported here range from $78.18 to $78.58. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 33,330 | $77.90 | $2,596,357.01 |
DisclosureSEC source: 0001127602-18-029453 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,034,432 F3 · price: Sale prices reported for the transactions reported here range from $77.17 to $78.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $23.60 | $1,180,000.00 |
DisclosureSEC source: 0001127602-18-029453 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-026965 · form4.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a five year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,624 | $75.00 | $196,790.03 |
DisclosureSEC source: 0001127602-18-026965 · form4.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017,762 F4 · price: Sale prices reported for the transactions reported here range from $74.68 to $75.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 47,376 | $74.11 | $3,511,243.81 |
DisclosureSEC source: 0001127602-18-026965 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,020,386 F3 · price: Sale prices reported for the transactions reported here range from $73.66 to $74.66. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $23.60 | $1,180,000.00 |
DisclosureSEC source: 0001127602-18-026965 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-024609 · form4.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a five year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 50,000 | $77.85 | $3,892,650.00 |
DisclosureSEC source: 0001127602-18-024609 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017,762 F3 · price: Sale prices reported for the transactions reported here range from $77.38 to $78.33. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $23.60 | $1,180,000.00 |
DisclosureSEC source: 0001127602-18-024609 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 02, 2018 Filed Jul 6, 2018 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-022892 · form4.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a five year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 02, 2018 Filed Jul 6, 2018 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $71.36 | $21,408.00 |
DisclosureSEC source: 0001127602-18-022892 · form4.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017,762 F4 · price: Sale prices reported for the transactions reported here range from $71.35 to $71.37. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 02, 2018 Filed Jul 6, 2018 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 49,700 | $70.80 | $3,518,874.31 |
DisclosureSEC source: 0001127602-18-022892 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,018,062 F3 · price: Sale prices reported for the transactions reported here range from $70.34 to $71.32. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 02, 2018 Filed Jul 6, 2018 00:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $23.60 | $1,180,000.00 |
DisclosureSEC source: 0001127602-18-022892 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-020081 · form4.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to the option have a five year vesting schedule. 20% vest on the first anniversary of the date of the grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 50,000 | $68.13 | $3,406,495.00 |
DisclosureSEC source: 0001127602-18-020081 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017,762 F3 · price: Sale prices reported for the transactions reported here range from $67.62 to $68.42. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $23.60 | $1,180,000.00 |
DisclosureSEC source: 0001127602-18-020081 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-017246 · form4.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,593 Underlying: Common Stock · 2,283 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 9, 2019, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 09, 2018 Filed May 11, 2018 23:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,496 | $0.00 Strike: $65.69 | $0.00 |
DisclosureSEC source: 0001127602-18-017246 · form4.xml · derivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,496 Underlying: Common Stock · 9,496 shares Expires 2028-05-09 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from May 9, 2018 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 9, 2019 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 01, 2018 Filed May 3, 2018 17:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-016152 · form4.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 01, 2018 Filed May 3, 2018 17:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 50,000 | $72.19 | $3,609,660.00 |
DisclosureSEC source: 0001127602-18-016152 · form4.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017,762 F3 · price: Sale prices reported for the transactions reported here range from $71.83 to $72.81. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2018 Filed May 3, 2018 17:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $23.60 | $1,180,000.00 |
DisclosureSEC source: 0001127602-18-016152 · form4.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.